{"id":"low-dose-sirolimus","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Mouth ulcers"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sirolimus is an mTOR inhibitor that blocks cell cycle progression by preventing the phosphorylation of downstream effectors. At low doses, it preferentially promotes the expansion of regulatory T cells (Tregs) while suppressing effector T cell proliferation, creating an immunomodulatory effect that may reduce autoimmune and inflammatory responses. This mechanism differs from higher-dose sirolimus used in transplantation, where broad immunosuppression is the goal.","oneSentence":"Low-dose sirolimus inhibits mTOR signaling to suppress immune cell proliferation and promote regulatory T cell differentiation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:37.164Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autoimmune and inflammatory conditions (Phase 3 investigational)"}]},"trialDetails":[{"nctId":"NCT02579967","phase":"PHASE2","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-19","conditions":"Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases","enrollment":354},{"nctId":"NCT05153668","phase":"EARLY_PHASE1","title":"Everolimus Trial in Laryngotracheal Stenosis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2022-09-30","conditions":"Idiopathic Subglottic Tracheal Stenosis","enrollment":8},{"nctId":"NCT04485559","phase":"PHASE1","title":"Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2020-12-09","conditions":"Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High Grade Glioma","enrollment":50},{"nctId":"NCT07475546","phase":"PHASE3","title":"Combination Gerotherapeutic Interventions for Healthspan Improvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgelessRx","startDate":"2025-07-23","conditions":"Healthspan Improvement, Aging, Longevity","enrollment":30},{"nctId":"NCT03587272","phase":"PHASE2","title":"Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease","status":"RECRUITING","sponsor":"Robert Nickel","startDate":"2018-04-17","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT07443826","phase":"PHASE1, PHASE2","title":"CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy","status":"RECRUITING","sponsor":"Unlimited Biotechnology LLC","startDate":"2026-03-31","conditions":"Age-related Muscle Decline","enrollment":12},{"nctId":"NCT04469530","phase":"PHASE2","title":"Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-09-16","conditions":"Solid Tumor","enrollment":55},{"nctId":"NCT06552169","phase":"PHASE2","title":"REgulatory T Cell Therapy to Achieve Immunosuppression REduction","status":"RECRUITING","sponsor":"Singulera Therapeutics Inc.","startDate":"2025-06-13","conditions":"Kidney Transplantation","enrollment":34},{"nctId":"NCT04408625","phase":"PHASE1, PHASE2","title":"Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prevail Therapeutics","startDate":"2020-11-09","conditions":"Frontotemporal Dementia","enrollment":35},{"nctId":"NCT05237687","phase":"PHASE2","title":"The Role of Sirolimus in Preventing Functional Decline in Older Adults","status":"RECRUITING","sponsor":"Irina Timofte","startDate":"2026-02","conditions":"Aging","enrollment":10},{"nctId":"NCT03922724","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-18","conditions":"Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases","enrollment":330},{"nctId":"NCT04411654","phase":"PHASE1, PHASE2","title":"Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prevail Therapeutics","startDate":"2021-06-29","conditions":"Gaucher Disease, Type 2","enrollment":7},{"nctId":"NCT03952637","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2019-08-19","conditions":"Lysosomal Diseases, Gangliosidosis, GM1","enrollment":54},{"nctId":"NCT07252050","phase":"PHASE1, PHASE2","title":"Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-01-01","conditions":"Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant","enrollment":24},{"nctId":"NCT02443818","phase":"PHASE2","title":"Sirolimus Effect on Hypertrophic Syndromes Related Gene PIK3CA","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2015-05","conditions":"Segmental Overgrowth Disorders Due to PIK3CA","enrollment":16},{"nctId":"NCT06261060","phase":"PHASE2","title":"Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-06-20","conditions":"Familial Platelet Disorder, Hematopoietic","enrollment":6},{"nctId":"NCT06358638","phase":"PHASE2","title":"Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2024-04-03","conditions":"Sickle Cell Disease","enrollment":12},{"nctId":"NCT01734512","phase":"PHASE2","title":"PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-12-13","conditions":"Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas","enrollment":65},{"nctId":"NCT07131644","phase":"PHASE2","title":"Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2025-09-13","conditions":"Kaposiform Hemangioendothelioma","enrollment":120},{"nctId":"NCT04362293","phase":"PHASE2","title":"Reduced Intensity Transplantation for Severe Sickle Cell Disease","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-04-30","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT03112603","phase":"PHASE3","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-29","conditions":"Graft-versus-host Disease (GVHD)","enrollment":330},{"nctId":"NCT07092618","phase":"PHASE2, PHASE3","title":"Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation","status":"RECRUITING","sponsor":"AgelessRx","startDate":"2024-12-17","conditions":"Longevity, GLP-1, Geroscience","enrollment":150},{"nctId":"NCT06960928","phase":"PHASE3","title":"Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2025-04-18","conditions":"Long COVID-19","enrollment":80},{"nctId":"NCT02123823","phase":"PHASE1","title":"BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-05-15","conditions":"Neoplasms","enrollment":164},{"nctId":"NCT07033858","phase":"NA","title":"Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation","status":"RECRUITING","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2025-03-01","conditions":"Kidney Transplant; Complications","enrollment":50},{"nctId":"NCT05132166","phase":"PHASE2","title":"A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-12-22","conditions":"Graft Vs Host Disease","enrollment":50},{"nctId":"NCT00113360","phase":"PHASE2","title":"RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-01","conditions":"Neuroendocrine Carcinoma, Islet Cell Carcinoma","enrollment":67},{"nctId":"NCT06942156","phase":"PHASE4","title":"Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2025-08-14","conditions":"Heart Transplant","enrollment":140},{"nctId":"NCT01499888","phase":"PHASE1, PHASE2","title":"Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2011-11-11","conditions":"Sickle Cell Disease","enrollment":45},{"nctId":"NCT05269849","phase":"PHASE2","title":"Sirolimus for Nosebleeds in HHT","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2022-03-16","conditions":"Hereditary Hemorrhagic Telangiectasia, Nosebleeds, Epistaxis","enrollment":10},{"nctId":"NCT03778996","phase":"PHASE2","title":"SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarcoma Oncology Research Center, LLC","startDate":"2020-01-03","conditions":"Sarcoma, Ewing, Sarcoma","enrollment":31},{"nctId":"NCT00977691","phase":"PHASE1, PHASE2","title":"Haploidentical PBMC Transplant for Severe Congenital Anemias","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2009-12-14","conditions":"Sickle Cell Anemia","enrollment":23},{"nctId":"NCT06673290","phase":"PHASE2, PHASE3","title":"Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-11-30","conditions":"Lymphatic Malformation","enrollment":150},{"nctId":"NCT06091332","phase":"PHASE2","title":"Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot Trial","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-01-05","conditions":"Cavernous Malformations, Intracerebral Hemorrhage, Brainstem Stroke","enrollment":75},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT06257420","phase":"","title":"Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions","status":"ENROLLING_BY_INVITATION","sponsor":"Simmaron Research Inc.","startDate":"2023-12-11","conditions":"Myalgic Encephalomyelitis, Long-COVID","enrollment":150},{"nctId":"NCT03413722","phase":"","title":"Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-02-01","conditions":"End Stage Renal Disease","enrollment":30},{"nctId":"NCT05594095","phase":"PHASE2","title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-12-30","conditions":"Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor","enrollment":620},{"nctId":"NCT05605665","phase":"PHASE1, PHASE2","title":"Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2022-12-05","conditions":"Sjögren's Syndrome","enrollment":30},{"nctId":"NCT04775173","phase":"PHASE2","title":"Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2021-02-17","conditions":"Kaposiform Hemangioendothelioma","enrollment":79},{"nctId":"NCT00061568","phase":"PHASE1, PHASE2","title":"Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias","status":"UNKNOWN","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2004-07-16","conditions":"Congenital Hemolytic Anemia, Sickle Cell Disease","enrollment":130},{"nctId":"NCT00235560","phase":"PHASE2","title":"Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2005-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT05324384","phase":"PHASE2","title":"Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2022-04-05","conditions":"Hemangioendothelioma","enrollment":30},{"nctId":"NCT06196996","phase":"NA","title":"Allogeneic Regenerative Islet Transplantation for the Treatment of Brittle Type 1 Diabetes Mellitus","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2021-09-14","conditions":"Brittle Type 1 Diabetes Mellitus","enrollment":18},{"nctId":"NCT03433183","phase":"PHASE2","title":"SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors","status":"COMPLETED","sponsor":"Sarcoma Alliance for Research through Collaboration","startDate":"2019-10-02","conditions":"Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1","enrollment":21},{"nctId":"NCT02642094","phase":"PHASE2","title":"Aging Mammary Stem Cells and Breast Cancer Prevention","status":"TERMINATED","sponsor":"LuZhe Sun","startDate":"2016-07","conditions":"Cancer of Breast","enrollment":58},{"nctId":"NCT01280669","phase":"PHASE2","title":"Intravitreal Sirolimus as Therapeutic Approach to Uveitis","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2022-09","conditions":"Uveitis, Intermediate Uveitis, Posterior Uveitis","enrollment":""},{"nctId":"NCT03386539","phase":"PHASE3","title":"Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score","status":"UNKNOWN","sponsor":"Boston Children's Hospital","startDate":"2018-01-29","conditions":"Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases","enrollment":211},{"nctId":"NCT00896012","phase":"PHASE4","title":"Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2008-01","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT04258423","phase":"PHASE3","title":"Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function","status":"TERMINATED","sponsor":"Indiana University","startDate":"2019-12-19","conditions":"Kidney Failure","enrollment":4},{"nctId":"NCT03797196","phase":"PHASE4","title":"RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2019-07-29","conditions":"Renal Transplant Recipients, Elderly Patients, Immunosuppression","enrollment":374},{"nctId":"NCT02913261","phase":"PHASE3","title":"Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-03-10","conditions":"Corticosteroid Refractory Acute Graft vs Host Disease","enrollment":310},{"nctId":"NCT04077515","phase":"PHASE4","title":"Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2019-05-01","conditions":"Hemangioma, Kaposiform Hemangioendothelioma","enrollment":92},{"nctId":"NCT02909335","phase":"PHASE3","title":"De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study","status":"WITHDRAWN","sponsor":"Rennes University Hospital","startDate":"2016-11","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT01976390","phase":"NA","title":"Comparing Everolimus and Sirolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2013-10-01","conditions":"Renal Failure","enrollment":60},{"nctId":"NCT01903473","phase":"PHASE2","title":"Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)","status":"TERMINATED","sponsor":"University of Liege","startDate":"2013-07","conditions":"Chronic Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease, Steroid Refractory Graft-Versus-Host Disease","enrollment":19},{"nctId":"NCT05294822","phase":"NA","title":"Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-09-30","conditions":"Diabetes","enrollment":20},{"nctId":"NCT01958190","phase":"PHASE4","title":"Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2011-02-07","conditions":"Liver Disease","enrollment":196},{"nctId":"NCT01453140","phase":"PHASE1, PHASE2","title":"In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2011-08","conditions":"Graft Versus Host Disease","enrollment":3},{"nctId":"NCT02959918","phase":"PHASE2","title":"Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid","status":"COMPLETED","sponsor":"Selecta Biosciences, Inc.","startDate":"2016-10","conditions":"Gout Chronic, Hyperuricemia","enrollment":152},{"nctId":"NCT02236572","phase":"PHASE2","title":"Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score","status":"TERMINATED","sponsor":"Yale University","startDate":"2014-11-29","conditions":"Breast Cancer","enrollment":17},{"nctId":"NCT03047980","phase":"PHASE2, PHASE3","title":"Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome","status":"COMPLETED","sponsor":"Anne Comi, MD","startDate":"2017-01","conditions":"Sturge-Weber Syndrome","enrollment":10},{"nctId":"NCT04906304","phase":"NA","title":"Comparison of Safety and Efficacy of de Novo Everolimus","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-01-01","conditions":"Cytomegalovirus Infections","enrollment":35},{"nctId":"NCT01653847","phase":"NA","title":"Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2013-02","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":88},{"nctId":"NCT00358657","phase":"PHASE2","title":"Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-05-24","conditions":"Immunodeficiency Syndrome, Severe Aplastic Anemia, Genetic Disorder","enrollment":14},{"nctId":"NCT00560963","phase":"PHASE1, PHASE2","title":"Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-10","conditions":"Advanced or Metastatic Pancreatic Adenocarcinoma","enrollment":21},{"nctId":"NCT01062555","phase":"PHASE1, PHASE2","title":"Calcineurin Inhibitor Sparing After Kidney Transplantation","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2006-10-01","conditions":"CNI Side Effects","enrollment":527},{"nctId":"NCT01526356","phase":"PHASE2","title":"Topical Rapamycin to Erase Angiofibromas in TSC","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2012-05","conditions":"Angiofibromas, Tuberous Sclerosis","enrollment":179},{"nctId":"NCT02908035","phase":"PHASE2","title":"Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)","status":"UNKNOWN","sponsor":"Mercator MedSystems, Inc.","startDate":"2017-03-03","conditions":"Chronic Limb Ischemia","enrollment":100},{"nctId":"NCT03618355","phase":"PHASE1","title":"Trial of eRapa in Prostate Cancer Patients","status":"COMPLETED","sponsor":"Rapamycin Holdings, Inc. dba Emtora Biosciences","startDate":"2018-08-28","conditions":"Prostate Cancer","enrollment":15},{"nctId":"NCT02428296","phase":"PHASE2","title":"Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation","status":"COMPLETED","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2015-04-23","conditions":"PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorder, Genetics","enrollment":39},{"nctId":"NCT02864706","phase":"PHASE4","title":"SCHEDULE Follow Up Visit 5-7 yr","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-01-18","conditions":"Heart Transplantation","enrollment":95},{"nctId":"NCT00434811","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Type 1 Diabetes Mellitus","enrollment":48},{"nctId":"NCT01358266","phase":"PHASE3","title":"Study Assessing Double-masked Uveitis Treatment","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2011-05","conditions":"Uveitis; Posterior, Disorder","enrollment":592},{"nctId":"NCT01878786","phase":"PHASE2, PHASE3","title":"A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys","status":"TERMINATED","sponsor":"Matthew Cooper","startDate":"2013-06","conditions":"Delayed Graft Function","enrollment":25},{"nctId":"NCT03866681","phase":"PHASE4","title":"Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory PNH","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-04-01","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":40},{"nctId":"NCT00311623","phase":"PHASE1, PHASE2","title":"Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2006-08","conditions":"Prostate Cancer","enrollment":32},{"nctId":"NCT02084446","phase":"PHASE4","title":"Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant","status":"COMPLETED","sponsor":"Ronaldo de Matos Esmeraldo, MD","startDate":"2012-12","conditions":"Transplantation Infection, Cytomegalovirus Infections","enrollment":120},{"nctId":"NCT00928018","phase":"PHASE3","title":"Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2009-06","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":139},{"nctId":"NCT02166177","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients","status":"COMPLETED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2014-06","conditions":"End-stage Liver Disease","enrollment":9},{"nctId":"NCT00074490","phase":"PHASE2","title":"Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-01-01","conditions":"Lymphoma, Leukemia, Myeloproliferative Disorders","enrollment":442},{"nctId":"NCT00526591","phase":"PHASE2","title":"Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer","status":"TERMINATED","sponsor":"Jorge A. Garcia, MD","startDate":"2007-09","conditions":"Prostate Cancer","enrollment":17},{"nctId":"NCT00782626","phase":"PHASE2","title":"Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2009-06","conditions":"Glioma, Low-grade Glioma, Astrocytoma","enrollment":23},{"nctId":"NCT00154284","phase":"PHASE3","title":"Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-07","conditions":"Organ Transplantation, Renal Transplantation","enrollment":114},{"nctId":"NCT02226861","phase":"PHASE1","title":"Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2014-08-26","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)","enrollment":24},{"nctId":"NCT01649609","phase":"NA","title":"Using mTOR Inhibitors in the Prevention of BK Nephropathy","status":"COMPLETED","sponsor":"Columbia University","startDate":"2012-03","conditions":"BK Viremia, BK Nephropathy","enrollment":40},{"nctId":"NCT01911546","phase":"PHASE2","title":"Role of Everolimus in Highly Sensitized Patients","status":"COMPLETED","sponsor":"Joseph Kahwaji, MD, MPH","startDate":"2013-06","conditions":"Highly-sensitized Kidney Transplant Recipients","enrollment":20},{"nctId":"NCT00955773","phase":"PHASE1","title":"A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-17","conditions":"Cancer","enrollment":64},{"nctId":"NCT00775593","phase":"PHASE2","title":"Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2008-12","conditions":"Leukemia","enrollment":60},{"nctId":"NCT01410448","phase":"PHASE3","title":"Everolimus in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Kidney Transplantation","enrollment":383},{"nctId":"NCT01313923","phase":"EARLY_PHASE1","title":"Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus","status":"TERMINATED","sponsor":"University of California, Irvine","startDate":"2011-02","conditions":"Pemphigus","enrollment":3},{"nctId":"NCT01462214","phase":"PHASE1, PHASE2","title":"Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer","status":"COMPLETED","sponsor":"Hans J. van der Vliet, MD, PhD","startDate":"2011-10","conditions":"Metastatic Renal Cell Cancer","enrollment":96},{"nctId":"NCT00891696","phase":"PHASE1","title":"Nutritional and Contractile Regulation of Muscle Growth","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2009-04","conditions":"Sarcopenia","enrollment":144},{"nctId":"NCT01181271","phase":"PHASE2","title":"Tandem Auto-Allo Transplant for Lymphoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-08","conditions":"Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma","enrollment":42},{"nctId":"NCT00265473","phase":"PHASE1, PHASE2","title":"MGA031, Sirolimus and Tacrolimus in Islet Transplantation","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2005-11","conditions":"Type 1 Diabetes Mellitus, Hypoglycemia","enrollment":5},{"nctId":"NCT00369161","phase":"PHASE4","title":"A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-06","conditions":"Renal Transplantation","enrollment":228},{"nctId":"NCT00514514","phase":"PHASE3","title":"Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":802},{"nctId":"NCT02015728","phase":"NA","title":"Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors","status":"UNKNOWN","sponsor":"Seattle Children's Hospital","startDate":"2013-12","conditions":"Recurrent Childhood Brain Tumor","enrollment":20},{"nctId":"NCT01649960","phase":"PHASE1","title":"Exercise and Low-Dose Rapamycin in Older Adults With CAD:Cardiac Rehabilitation And Rapamycin in Elderly (CARE) Trial","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-08","conditions":"Aging, CAD","enrollment":13},{"nctId":"NCT00504543","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":311}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":75,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rapamycin"],"phase":"phase_3","status":"active","brandName":"Low-dose sirolimus","genericName":"Low-dose sirolimus","companyName":"Icahn School of Medicine at Mount Sinai","companyId":"icahn-school-of-medicine-at-mount-sinai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose sirolimus inhibits mTOR signaling to suppress immune cell proliferation and promote regulatory T cell differentiation. Used for Autoimmune and inflammatory conditions (Phase 3 investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}